(210 days)
Not Found
Unknown
The summary describes "automatic labeling, visualization, and volumetric quantification" and a "segmentation system relies on a number of atlases". While these tasks can be performed using traditional image processing techniques, they are also common applications of AI/ML in medical imaging. The document does not explicitly mention AI, ML, or deep learning, nor does it provide details about the algorithms used that would definitively confirm or deny the use of AI/ML. The description of the test set and performance studies is consistent with both traditional and AI/ML-based approaches.
No.
The device is a medical imaging processing application that provides complementary information for evaluation and assessment, not direct therapy.
Yes
The text describes the device as being "intended to provide the trained medical professional with complementary information for the evaluation and assessment of MR brain images and to aid the trained medical professional in quantitative reporting," which indicates it assists in medical diagnosis.
Yes
The device is described as a "post-processing analysis software" and a "non-invasive medical imaging processing application" that runs as a "plugin" on existing hardware platforms (GE Advantage Workstation or AW Server). There is no mention of any proprietary hardware components included with the device itself.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Quantib™ Brain's Function: Quantib™ Brain processes medical images (MR images) taken from the body, not samples from the body. It analyzes the structure and volume of the brain based on these images.
- Intended Use: The intended use clearly states it's a "medical imaging processing application" for analyzing MR brain images. It provides "complementary information for the evaluation and assessment of MR brain images."
- Device Description: The device description reinforces that it's "post-processing analysis software" for MR images.
Therefore, Quantib™ Brain falls under the category of medical imaging software or a medical device that processes imaging data, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
Quantib™ Brain is a non-invasive medical imaging processing application that is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures from a set of magnetic resonance (MR) images. The Quantib™ Brain output consists of segmentations, visualizations and volumetric measurements of grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF). The output also visualizes and quantifies white matter hyperintensity (WMH) candidates. Users need to review and if necessary, edit WMH candidates using the provided tools, before validation of the WMHs. It is intended to provide the trained medical professional with complementary information for the evaluation and assessment of MR brain images and to aid the trained medical professional in quantitative reporting. Quantib™ Brain is a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms.
Product codes
LLZ
Device Description
Quantib™ Brain is post-processing analysis software for the GE Advantage (AW 4.7) or AW Server (AWS 3.2) platforms using Volume Viewer Apps. 12.3 Ext 6. It is intended for automatic labeling, visualization, and volumetric quantification of identifiable brain structures from magnetic resonance images (a 3D T1weighted MR image, with an additional T2-weighted FLAIR MR image for white matter hyperintensities (WMH) segmentation). The segmentation system relies on a number of atlases each consisting of a 3D T1-weighted MR image and a label map dividing the MR image into different tissue segments. Quantib™ Brain provides quantitative information on both the absolute and relative volume of the segmented regions. The automatic WMH segmentation is to be reviewed and if necessary, edited by the user before validation of the segmentation, after which volumetric information is accessible. It is intended to provide the trained medical professional with complementary information for the evaluation and assessment of MR brain images and to aid the radiology specialist in quantitative reporting.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Magnetic resonance (MR) images (a 3D T1weighted MR image, with an additional T2-weighted FLAIR MR image for white matter hyperintensities (WMH) segmentation)
Anatomical Site
Brain
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Trained medical professional, radiology specialist. Post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
For the brain volumetry protocol (segmentation and measures of GM, WM, CSF, and ICV) the test set included 33 T1w MR images. The set was carefully selected to include data from multiple vendors and a series of representable scan settings. For each scan we selected six (6) slices for comparison. The test set for the WMH protocol included 30 3D T1w images with corresponding T2w FLAIR images. This set also represented various scan settings. WMHs were manually segmented on the T2w FLAR images and compared to Quantib™ Brain automatic segmentation output.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Quality and safety: Quantib™ Brain was designed in compliance with ISO 14971 and IEC 62304. Quality assurance measures applied include Risk and hazard analysis, Design reviews, Unit level testing, Integration testing, System testing, Performance testing, Usability engineering.
Algorithm performance:
For brain volumetry (GM, WM, CSF, ICV): Test set of 33 T1w MR images.
CSF: Dice index 0.78 ± 0.05, Absolute difference of the relative volumes 1.6 ± 1.0 pp.
GM: Dice index 0.83 ± 0.02, Absolute difference of the relative volumes 2.8 ± 1.9 pp.
WM: Dice index 0.86 ± 0.02, Absolute difference of the relative volumes 2.6 ± 1.6 pp.
ICV: Dice index 0.97 ± 0.01.
For WMH protocol: Test set of 30 3D T1w images with corresponding T2w FLAIR images.
The average Dice overlap between the manual segmentations and Quantib™ Brain segmentations was 0.61 ± 0.13. The absolute difference of the relative volumes (for WMHs) was 0.6 ± 0.7 percentage points.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Dice index, Absolute difference of the relative volumes [pp].
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features the department's name in a circular arrangement around a symbol. The symbol is a stylized representation of three human profiles facing right, with flowing lines suggesting movement or connection.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 17, 2016
Quantib B.V. Floor van Leeuwen Quality & Regulatory Manager Westblaak 106 3012 KM Rotterdam NETHERLANDS
Re: K153351 Trade/Device Name: QuantibTM Brain 1 Regulation Number: 21 CFR 892.2050 Regulation Name: Picture Archiving and Communications System Regulatory Class: Class II Product Code: LLZ Dated: May 19, 2016 Received: May 23, 2016
Dear Floor van Leeuwen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Michael D'Hara
For
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K-153351
Device Name Quantib™ Brain 1
Indications for Use (Describe)
Quantib™ Brain is a non-invasive medical imaging processing application that is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures from a set of magnetic resonance (MR) images. The Quantib™ Brain output consists of segmentations, visualizations and volumetric measurements of grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF). The output also visualizes and quantifies white matter hyperintensity (WMH) candidates. Users need to review and if necessary, edit WMH candidates using the provided tools, before validation of the WMHs. It is intended to provide the trained medical professional with complementary information for the evaluation and assessment of MR brain images and to aid the trained medical professional in quantitative reporting. Quantib™ Brain is a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Figure/0 description: The image shows the logo for Quantib, a company focused on image-informed medicine. The logo features a stylized graphic to the left, composed of stacked, offset rectangles in shades of blue, orange, and brown, creating a visual effect reminiscent of data or imaging slices. To the right of the graphic is the company name "Quantib" in a teal sans-serif font, with the tagline "Image Informed Medicine" in a smaller font size underneath.
510(k) Summary
I. SUBMITTER
Quantib B.V. Westblaak 106 3012 KM Rotterdam Phone: (+31) 108 41 17 49 Contact Person: Floor van Leeuwen Date Prepared: November 18th, 2015
II. DEVICE
Name of Device: Quantib™ Brain 1 Common or Usual Name: Quantib™ Brain Classification Name: System, image processing, radiology (892.2050) Regulatory Class: II Product Code: Picture archiving and communication system (LLZ)
III. PREDICATE DEVICE
Device: QBrain® Manufacturer: Medis medical imaging systems 510(k) Reg. No: K050703 This predicate has not been subject to a design-related recall. Regulatory Class: II Product Code: Picture archiving and communication system (LLZ)
IV. DEVICE DESCRIPTION
Quantib™ Brain is post-processing analysis software for the GE Advantage (AW 4.7) or AW Server (AWS 3.2) platforms using Volume Viewer Apps. 12.3 Ext 6. It is intended for automatic labeling, visualization, and volumetric quantification of identifiable brain structures from magnetic resonance images (a 3D T1weighted MR image, with an additional T2-weighted FLAIR MR image for white matter hyperintensities (WMH) segmentation). The segmentation system relies on a number of atlases each consisting of a 3D T1-weighted MR image and a label map dividing the MR image into different tissue segments. Quantib™ Brain provides quantitative information on both the absolute and relative volume of the segmented regions. The automatic WMH segmentation is to be reviewed and if necessary, edited by the user before validation of the segmentation, after which volumetric information is accessible. It is intended to provide the trained medical professional with complementary information for the evaluation and assessment of MR brain images and to aid the radiology specialist in quantitative reporting.
4
V. INTENDED USE
Intended use Quantib™ Brain
Quantib™ Brain is a non-invasive medical imaging processing application that is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures from a set of magnetic resonance (MR) images. The Quantib™ Brain output consists of segmentations, visualizations and volumetric measurements of grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF). The output also visualizes and quantifies white matter hyperintensity (WMH) candidates. Users need to review and if necessary, edit WMH candidates using the provided tools, before validation of the WMHs. It is intended to provide the trained medical professional with complementary information for the evaluation and assessment of MR brain images and to aid the trained medical professional in quantitative reporting. Quantib™ Brain is a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms.
Intended us predicate device QBrain®
Intended use
The QBrain® software has been developed for the objective and reproducible analysis of MR images of the brain. It performs quantitative analyses on MR brain image based on automatic segmentation. More specifically, it quantifies the volumes of intracranial cavities, areas that contain cerebrospinal fluid (CSF), and white matter hyperintensities (lesions).
Indications for use
QBrain® is able to read DCIOM MR image from all major MRI vendors. Mask data, generated by automatic segmentation and/or manual editing, and quantitative results ca be saved in separate files enabling the comparison of results from different users and easy export to standard spreadsheet software.
Neur-(radio)logists in hospitals and specialists in core labs use the QBrain stand-alone analytical software package in image post-processing. The provided objective and quantitative values support the diagnostic decision process or are used in the evaluation of follow-up studies about on and/or therapy response.
Intended use comparison
Both device and predicate device are designed to assist trained medical professionals, i.e. radiologists, in the evaluation and assessment of MR brain images with a set of tools for visualizing the location and quantification of brain structures. Both are intended to automate the current manual process of identifying, labeling, and quantifying the volume of segmentable brain structures identified on MR images.
5
VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS
Both device and predicate device are software for the automatic labeling, visualization, and quantification (segmentation) of the volume of specific areas of the brain. Atlas-based segmentation is the technological principle for both devices.
Both devices require a 3D T1w MR image for tissue-type segment White Matter Hyperintensities (WMH), Quantib™ Brain requires an additional T2w FLAIR scan. Histogram analysis and trained classifiers are used in combination with atlas-based tissue segmentation to improve the accuracy and specificity of WMH segmentation.
Quantib™ Brain reports the following measurements: absolute volume and relative to ICV) of grey matter (GM), white matter (WM), cerebrospinal fluid (CSF), and intracranial volume (ICV); brain volume (=GM+WM); total volume of WM hyperintensities (WMH); relative WMH volume (relative to WM); total number of WMH.
| Quantib™ Brain | K050703 QBrain® |
|---|---|
| Brain tissue and WMH segmentation | Brain tissue segmentation (intracranial |
| tissue volume GM+WM, CSF volume, lobe | |
| volumes, cerebellum volume). WMH | |
| segmentation (total WMH volume). | |
| Absolute and relative volumes | Absolute volumes |
| Software plugs into the AW and AW server | |
| platforms | Stand-alone application |
Following are the differences between Quantib™ Brain and the predicate device:
Table 5-1 Differences with predicate device
VII. PERFORMANCE DATA:
1. Quality and safety
Quantib™ Brain was designed in compliance with the following process standards:
- ISO 14971 – Medical devices - Application of risk management to medical devices
- . IEC 62304 – Medical device software – Software life cycle processes
The following quality assurance measures were applied to Quantib™ Brain development:
- Risk and hazard analysis
- Design reviews
- Unit level testing
- . Integration testing
- System testing
- Performance testing
- . Usability engineering
2. Algorithm performance
6
To validate the quality of Quantib™ Brain volume measurements and segmentations, we compared the relative brain tissue volumes to relative volumes derived from manual segmentations for the same scan. We performed this analysis for GM, WM, CSF, ICV, and WMHs.
For the brain volumetry protocol (segmentation and measures of GM, WM, CSF, and ICV) the test set included 33 T1w MR images. The set was carefully selected to include data from multiple vendors and a series of representable scan settings. For each scan we selected six (6) slices for comparison. The results are summarized in Table 5-2.
| | Dice index | Absolute difference of the
relative volumes [pp] |
|-----|-------------|-----------------------------------------------------|
| CSF | 0.78 ± 0.05 | 1.6 ± 1.0 |
| GM | 0.83 ± 0.02 | 2.8 ± 1.9 |
| WM | 0.86 ± 0.02 | 2.6 ± 1.6 |
| ICV | 0.97 ± 0.01 | |
Table 5-2 Results of comparison between manual and automatic brain tissue seqmentation. Reported values are averages ± std. dev., computed over 6 segmented slices of 33 scans. The Dice index provides a measure for overlap of manual and automatic segmentations (1 = perfect overlap). The absolute differences of the relative volumes (of the brain tissues) are averages ± std. dev. in percentage points.
The test set for the WMH protocol included 30 3D T1w images with corresponding T2w FLAIR images. This set also represented various scan settings. WMHs were manually segmented on the T2w FLAR images and compared to Quantib™ Brain automatic segmentation output. The average Dice overlap between the manual segmentations and Quantib™ Brain segmentations was 0.61 ± 0.13. The absolute difference of the relative volumes (for WMHs) was 0.6 ± 0.7 percentage points.
VIII. CONCLUSIONS
By virtue of its intended use and physical and technological characteristics, Quantib™ Brain is substantially equivalent to a device that has been approved for marketing in the United States. The performance data shows that Quantib™ Brain is as safe and effective as the predicate device.